[go: up one dir, main page]

WO2012033789A3 - Traitement de maladies - Google Patents

Traitement de maladies Download PDF

Info

Publication number
WO2012033789A3
WO2012033789A3 PCT/US2011/050612 US2011050612W WO2012033789A3 WO 2012033789 A3 WO2012033789 A3 WO 2012033789A3 US 2011050612 W US2011050612 W US 2011050612W WO 2012033789 A3 WO2012033789 A3 WO 2012033789A3
Authority
WO
WIPO (PCT)
Prior art keywords
diketopiperazme
animal
prodrug
pharmaceutically
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/050612
Other languages
English (en)
Other versions
WO2012033789A2 (fr
Inventor
David Bar-Or
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMI Acquisition Corp
Original Assignee
DMI Acquisition Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK13109875.6A priority Critical patent/HK1182617B/en
Priority to ES11824038.1T priority patent/ES2611878T3/es
Priority to EA201390347A priority patent/EA023932B1/ru
Priority to AU2011299353A priority patent/AU2011299353B2/en
Priority to CA2810834A priority patent/CA2810834C/fr
Priority to PH1/2013/500449A priority patent/PH12013500449A1/en
Priority to SG2013015680A priority patent/SG187986A1/en
Priority to NZ607600A priority patent/NZ607600A/en
Priority to MX2013002566A priority patent/MX343160B/es
Priority to BR112013005432A priority patent/BR112013005432A8/pt
Priority to JP2013528256A priority patent/JP5941047B2/ja
Priority to EP11824038.1A priority patent/EP2613795B1/fr
Application filed by DMI Acquisition Corp filed Critical DMI Acquisition Corp
Priority to KR1020137008193A priority patent/KR101822951B1/ko
Priority to CN201180053553.8A priority patent/CN103200952B/zh
Publication of WO2012033789A2 publication Critical patent/WO2012033789A2/fr
Publication of WO2012033789A3 publication Critical patent/WO2012033789A3/fr
Priority to IL224931A priority patent/IL224931A/en
Priority to ZA2013/01601A priority patent/ZA201301601B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode pour inhiber l'hyperperméabilité vasculaire chez un animal nécessitant un tel traitement. Cette méthode consiste à administrer à cet animal une dose efficace d'une dicétopipérazine, d'un promédicament d'une dicétopipérazine ou d'un sel pharmaceutiquement acceptable de l'une ou l'autre de ces substances, la dicétopipérazine possédant la formule présentée dans la description. L'invention concerne également une méthode de modulation du cytosquelette d'une cellule endothéliale chez un animal. Ladite méthode consiste à administrer à cet animal une dose efficace d'une dicétopipérazine, d'un promédicament d'une dicétopipérazine ou d'un sel pharmaceutiquement acceptable de l'une ou l'autre de ces substances, la dicétopipérazine possédant la formule présentée dans la description. L'invention se rapporte en outre à une trousse comprenant une dicétopipérazine, un promédicament d'une dicétopipérazine ou un sel pharmaceutiquement acceptable de l'une ou l'autre de ces substances pour l'animal, la dicétopipérazine possédant la formule présentée dans la description.
PCT/US2011/050612 2010-09-07 2011-09-07 Traitement de maladies Ceased WO2012033789A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
JP2013528256A JP5941047B2 (ja) 2010-09-07 2011-09-07 疾患を治療するための医薬品及び同医薬品を含むキット
EA201390347A EA023932B1 (ru) 2010-09-07 2011-09-07 Лечение заболеваний, связанных с гиперпроницаемостью сосудов
AU2011299353A AU2011299353B2 (en) 2010-09-07 2011-09-07 Treatment of diseases
CA2810834A CA2810834C (fr) 2010-09-07 2011-09-07 Utilisation de diketopiperazines en vue d'inhiber l'hyperpermeabilite vasculaire
PH1/2013/500449A PH12013500449A1 (en) 2010-09-07 2011-09-07 Treatment of diseases
SG2013015680A SG187986A1 (en) 2010-09-07 2011-09-07 Treatment of diseases
NZ607600A NZ607600A (en) 2010-09-07 2011-09-07 Compositions for the treatment of diseases
MX2013002566A MX343160B (es) 2010-09-07 2011-09-07 Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
BR112013005432A BR112013005432A8 (pt) 2010-09-07 2011-09-07 tratamento de doenças
HK13109875.6A HK1182617B (en) 2010-09-07 2011-09-07 Diketopiperazines for treating vascular hyperpermeability
ES11824038.1T ES2611878T3 (es) 2010-09-07 2011-09-07 Dicetopiperazinas para tratar la hiperpermeabilidad vascular
EP11824038.1A EP2613795B1 (fr) 2010-09-07 2011-09-07 Diketopiperazines pour traiter l'hyperperméabilité vasculaire
KR1020137008193A KR101822951B1 (ko) 2010-09-07 2011-09-07 질병의 치료
CN201180053553.8A CN103200952B (zh) 2010-09-07 2011-09-07 疾病的治疗
IL224931A IL224931A (en) 2010-09-07 2013-02-26 Diketopiperazines for treatment of vascular hyperpermeability
ZA2013/01601A ZA201301601B (en) 2010-09-07 2013-03-01 Treatment of diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38040410P 2010-09-07 2010-09-07
US61/380,404 2010-09-07

Publications (2)

Publication Number Publication Date
WO2012033789A2 WO2012033789A2 (fr) 2012-03-15
WO2012033789A3 true WO2012033789A3 (fr) 2012-05-31

Family

ID=45771136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/050612 Ceased WO2012033789A2 (fr) 2010-09-07 2011-09-07 Traitement de maladies

Country Status (18)

Country Link
US (3) US20120058934A1 (fr)
EP (1) EP2613795B1 (fr)
JP (2) JP5941047B2 (fr)
KR (1) KR101822951B1 (fr)
CN (1) CN103200952B (fr)
AU (1) AU2011299353B2 (fr)
BR (1) BR112013005432A8 (fr)
CA (1) CA2810834C (fr)
CO (1) CO6710904A2 (fr)
EA (1) EA023932B1 (fr)
ES (1) ES2611878T3 (fr)
IL (1) IL224931A (fr)
MX (1) MX343160B (fr)
NZ (1) NZ607600A (fr)
PH (1) PH12013500449A1 (fr)
SG (2) SG10201507120TA (fr)
WO (1) WO2012033789A2 (fr)
ZA (1) ZA201301601B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311269E (pt) 2000-08-04 2012-05-10 Dmi Biosciences Inc Método de utilização de dicetopiperazinas e composição que contém as mesmas
CN103191409A (zh) 2003-05-15 2013-07-10 Dmi生物科学公司 T-细胞介导的疾病的治疗
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
WO2012033789A2 (fr) * 2010-09-07 2012-03-15 Dmi Acquisition Corp. Traitement de maladies
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (fr) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Traitement de maladies articulaires dégénératives avec da-dkp (= diketopiperazine aspartyl-alanyl)
CA2846394A1 (fr) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Traitement de la rhinite
MX2015010937A (es) 2013-03-15 2015-10-29 Ampio Pharmaceuticals Inc Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.
CN105307514B (zh) 2013-06-10 2018-11-27 三得利控股株式会社 含有二酮哌嗪的植物提取物及其制造方法
CN103913853A (zh) * 2013-07-05 2014-07-09 马准吾 具备冷感包覆层的隐形眼镜
RU2020136589A (ru) 2014-08-18 2020-12-24 Ампио Фармасьютикалз, Инк. Лечение дегенеративных заболеваний суставов
EP3310375A4 (fr) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies
KR20180030915A (ko) 2015-07-27 2018-03-26 산토리 홀딩스 가부시키가이샤 고리형 디펩티드 및 감미료를 함유하는 조성물
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
CN105879005A (zh) * 2016-02-01 2016-08-24 四川好医生攀西药业有限责任公司 一种治疗溃疡性结肠炎的药物组合物及其制备方法和应用
WO2018022695A1 (fr) * 2016-07-26 2018-02-01 Ampio Pharmaceuticals, Inc. Traitement de maladies à médiation assurée par une hyperperméabilité vasculaire
CN117577321A (zh) 2017-08-08 2024-02-20 费森尤斯医疗保健控股公司 用于治疗和评估慢性肾脏疾病的进程的系统和方法
JP6741280B2 (ja) * 2018-03-29 2020-08-19 株式会社ウォーターエージェンシー Ａｃｅ阻害、血圧上昇抑制、又は血圧降下に用いられる組成物、及びその製造方法
WO2021195265A1 (fr) 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Méthodes de traitement de maladies associées à des virus respiratoires
CN113754598B (zh) * 2021-09-29 2023-06-06 四川大学 含环肽结构的二胺、聚酰亚胺及其制备方法
CN119970736A (zh) * 2025-01-23 2025-05-13 澳门科技大学 组蛋白去乙酰化酶4小分子抑制剂的合成方法和抗血管内皮衰老的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052381A1 (en) * 2000-08-04 2002-05-02 David Bar-Or Method of using diketopiperazines and composition containing them
WO2009042193A1 (fr) * 2007-09-25 2009-04-02 Abbott Laboratories Composés d'octahydropentalène en tant qu'antagonistes d'un récepteur de chimiokine
WO2012033789A2 (fr) * 2010-09-07 2012-03-15 Dmi Acquisition Corp. Traitement de maladies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000327575A (ja) * 1999-05-26 2000-11-28 Teika Seiyaku Kk ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体
CN1791420A (zh) * 2003-05-15 2006-06-21 Dmi生物科学公司 T－细胞介导的疾病的治疗
CN103191409A (zh) * 2003-05-15 2013-07-10 Dmi生物科学公司 T-细胞介导的疾病的治疗
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
JP2013537195A (ja) * 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052381A1 (en) * 2000-08-04 2002-05-02 David Bar-Or Method of using diketopiperazines and composition containing them
WO2009042193A1 (fr) * 2007-09-25 2009-04-02 Abbott Laboratories Composés d'octahydropentalène en tant qu'antagonistes d'un récepteur de chimiokine
WO2012033789A2 (fr) * 2010-09-07 2012-03-15 Dmi Acquisition Corp. Traitement de maladies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAMANTA ET AL.: "Crystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 46, 14 November 2008 (2008-11-14), pages 31617 - 31624, XP008149417 *
SCHLINGEMANN ET AL.: "Role of vascular permeability factor/vascular endothelial growth factor in eye disease", BR J OPHTHALMOL, vol. 81, 1997, pages 501 - 512, XP008162953 *

Also Published As

Publication number Publication date
KR20140003399A (ko) 2014-01-09
ES2611878T3 (es) 2017-05-11
JP5941047B2 (ja) 2016-06-29
JP2016145261A (ja) 2016-08-12
CA2810834A1 (fr) 2012-03-15
EP2613795A2 (fr) 2013-07-17
ZA201301601B (en) 2018-12-19
EP2613795A4 (fr) 2013-10-30
AU2011299353B2 (en) 2016-02-25
US20120058934A1 (en) 2012-03-08
HK1182617A1 (en) 2013-12-06
US20210052578A1 (en) 2021-02-25
US20200016152A1 (en) 2020-01-16
SG10201507120TA (en) 2015-10-29
EP2613795B1 (fr) 2016-10-26
BR112013005432A8 (pt) 2017-12-05
IL224931A (en) 2017-05-29
CN103200952A (zh) 2013-07-10
EA023932B1 (ru) 2016-07-29
MX343160B (es) 2016-10-26
CN103200952B (zh) 2016-04-06
BR112013005432A2 (pt) 2016-06-07
CO6710904A2 (es) 2013-07-15
CA2810834C (fr) 2017-03-21
NZ607600A (en) 2015-05-29
AU2011299353A1 (en) 2013-03-14
MX2013002566A (es) 2013-06-18
JP2013537194A (ja) 2013-09-30
EA201390347A1 (ru) 2013-07-30
KR101822951B1 (ko) 2018-01-29
PH12013500449A1 (en) 2019-10-11
SG187986A1 (en) 2013-03-28
WO2012033789A2 (fr) 2012-03-15

Similar Documents

Publication Publication Date Title
WO2012033789A3 (fr) Traitement de maladies
EA201201648A1 (ru) Стимуляторы sgc
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
HK1245677A1 (zh) 用於治疗炎症和癌症的杂环itk抑制剂
EP4218759A3 (fr) Traitment combiné
NZ597517A (en) 5-fluoropyrimidinone derivatives
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
MA33939B1 (fr) 5-alcynyl-pyrimidines
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
UA104203C2 (en) Microbiocidal heterocycles
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
WO2013106761A3 (fr) Agents antimicrobiens
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
EA201200036A1 (ru) Способ лечения заболеваний
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
WO2012037547A3 (fr) Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose
EA201270728A1 (ru) Пуриновые соединения
PH12014501396A1 (en) Synergistic herbicidal composition containing fluroxypyr and glyphosate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180053553.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11824038

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/002566

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013528256

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2810834

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12013500449

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2011299353

Country of ref document: AU

Date of ref document: 20110907

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137008193

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011824038

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13089531

Country of ref document: CO

Ref document number: 2011824038

Country of ref document: EP

Ref document number: 201390347

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013005432

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013005432

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130306